Medical News
Microbiota Thrombus Colonization may influence AtheRo-thromb...
Diabetes Res Clin Pract.
Hyperglycemia during STEMI may increase coronary thrombus burden via gut and thrombus microbiota dysbiosis...
15 Jan 2021
Cardiovascular Dysfunction in Children Exposed to Preeclamps...
J Am Soc Echocardiogr.
In-utero exposure to preeclampsia has an effect on the vascular function in children aged 2-10 years, primarily...
15 Jan 2021
Primary Percutaneous Coronary Intervention in Nonagenarians:...
BMC Cardiovasc Disord.
In this series of selected nonagenarians presenting with acute myocardial infarction, those undergoing PPCI...
15 Jan 2021
Triglyceride–Glucose Index is associated with the Risk of My...
Cardiovasc Diabetol.
Elevated levels of the baseline and long-term TyG index are associated with an increased risk of MI. This finding...
14 Jan 2021
eCMEs
Key Trials
PIONEER-HF: Efficacy and Safety of Sacubitril/Valsartan in ADHF Patients as per the Dose Level Achieved
Sacubitril/valsartan exhibited generally consistent efficacy and safety across various dose levels in hemodynamically stabilized patients with ADHF...
Loop Diuretic Dose Change and the Outcomes in Chronic HF Patients: Insights from the ESC-EORP HF Long-Term Registry
This large-scale study demonstrated very low rate of loop diuretic (LD) dose down-titration in chronic HF patients, depicting the high discordance...
Impact of Sacubitril/Valsartan on Sudden Cardiac Death as per ICD Use and HF Cause
This sub-group analysis of the PARADIGM HF study demonstrates under-usage of ICD in patients with HFrEF despite reduction in sudden cardiac death....
PIONEER HF: Sacubitril/valsartan in African-American Patients with ADHF
This subgroup analysis of the PIONEER-HF trial demonstrated sacubitril/valsartan to be equally effective and safe in African-American and non-...
Slide Library
Medical Management Strategy of CTEPH: Role of Riociguat
Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH
Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...
Chronic Thromboembolic Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...
Diabetic Dyslipidemia
Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...
Our Publications
Rivazest (Rivaroxaban) Monograph
Rivaroxaban is a potent, selective, orally active direct inhibitor of the activated serine protease Factor X (FXa), which plays a central role in...
Telyse (Tenecteplase) Monograph
In the management of STEMI in India, pharmacoinvasive strategy involving thrombolytics is the preferred therapy in cases of delays in primary PCI....
Mexiletine FAQ Booklet
Mexiletine is a class 1B antiarrhythmic agent, which blocks the sodium channels and is indicated in suppression of ventricular arrhythmias. The...
Mexohar (Mexiletine) Monograph
About 5% of patients with cardiac arrhythmias or with heart failure are diagnosed with a ventricular tachycardia. Recurrent Ventricular Tachycardia...
Patient Education
Understanding Angioplasty
Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.
Understanding Obesity
This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss.
Hypertension
Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure.
.jpg)
Poll
What percent of your patients who need oral anticoagulation, receive warfarin?
<20%
20-40%
40-50%
50-70%
70-80%
Almost all
Total votes: 23